Trial results for the Phase 2 study (NCT03835819) investigating pembrolizumab in combination with mirvetuximab soravtansine for endometrial cancer were posted on ClinicalTrials.gov on 2025-05-15. The study reported an objective response rate of 28 percentage of participants for the combination therapy.
Background
The study NCT03835819, titled 'A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC),' investigated a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study were mirvetuximab soravtansine (IMGN853) and pembrolizumab.
Trial design
The study NCT03835819 was a Phase 2 trial that enrolled 18 participants with endometrial cancer. The study investigated the combination of mirvetuximab soravtansine (IMGN853) and pembrolizumab. Participants received this drug combination as a potential treatment.
Key results
The trial results for the IMGN853 + Pembrolizumab group included the following outcome measurements:
- The Objective Response Rate was 28 percentage of participants.
- Progression-Free Survival at 6 Months (PFS6) was observed in 4 Participants.
- The median Progression-free Survival was 2.73 months.
- The median Overall Survival was 11.3 months.
- The median Duration of Response was 7.1 months.
What this means
The results from this Phase 2 study provide initial data on the activity of the combination of pembrolizumab and mirvetuximab soravtansine in patients with endometrial cancer. The observed objective response rate of 28 percentage of participants, along with median progression-free survival of 2.73 months and overall survival of 11.3 months, offers insights into the potential of this regimen. These findings contribute to the understanding of combination therapies in this patient population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03835819, titled 'A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC),' were posted on 2025-05-15 on clinicaltrials.gov.